Posts Tagged ‘PerkinElmer’

2012 Omics Tools and Molecular Diagnostics: average CEO Compensation at Publicly Traded Firms

Reporter: Aviva Lev-Ari, PhD, RN

GenomeWeb Feature: CEOs at Omics Tools, MDx Firms See Compensation Rise an Average 7 Percent in 2012

July 15, 2013

NEW YORK (GenomeWeb News) – The average CEO compensation at publicly traded omics tools and molecular diagnostics firms rose nearly 7 percent year over year in 2012, according to documents filed with the US Securities and Exchange Commission.

Based on proxy statements filed by 28 of the 29 firms in the GenomeWeb Daily NewsIndex, CEO compensation for 2012 averaged more than $4.8 million, up from a little less than $4.5 million in 2011.

One firm, Rosetta Genomics, based in Rehovot, Israel, did not report compensation for its CEO, Kenneth Berlin, either in 2011 or 2012. The firm did not respond to requests for information.

The base salary for CEOs in 2012 averaged $686,017, also up about 7 percent from $644,109 in 2011, according to the proxy statements.

As a total dollar amount, CEO compensation for the 28 companies in the GWDN Index reached about $135.3 million last year, up about 8 percent from $125.7 million, while the base salaries in 2012 totaled $19.2 million, an increase of 6 percent from $18.0 million in 2011.

Executive compensation across all industries has become a lightning rod in recent years with shareholders and the general public seeking greater transparency in how compensation is determined and justification for sometimes extravagant pay perks.

According to Susan Stemper, managing director at executive compensation consulting firm Pearl Meyer & Partners, investors need to scrutinize executive compensation because they provide a window into the strategic direction that a board has set for the business and whether a board’s decisions around CEO pay are competitive and appropriate for the business.

Investors need to focus on how executive compensation levels are designed, said Stemper. “I’d say, ‘Don’t look at the numbers, look at the design,'” she toldGenomeWeb Daily News, adding that, in particular, it is important to focus on achievements made in the past year and how they compare to the company’s goals and objectives.

Setting appropriate compensation levels for executives, which include stock and other option awards, is a tricky art that, in addition to using measurable metrics, often include more difficult to measure factors that are meant to reward executives for their performance during the past year.

Such pay-for-performance components, however, present special challenges to omics tools/MDx firms, Stemper said.

“The challenge is when you’re looking at these sectors where the return from the research and development — if it follows at all — perhaps only follow quarters or years after that initial investment has been made,” she said. “The conundrum that we face is trying to look at this year’s pay and trying to align it with this year’s financial performance of the business.”

In the omics/MDx sector, “you need a lot of shots on goal” before a target is hit, and “you can’t count on all those shots on goal happening in a given year,” Stemper said. “So does it really make sense not to grant the stock, or not award the stock because we didn’t make the shot on goals when we recognize that that is just part of how we do business?”

As a result, companies in the omics tools/MDx space have come to rely on time-vested stock and option grants, which become exercisable after a defined amount of time has elapsed.

“To me, those are the perfect performance-based vehicles, because if the stock price doesn’t perform, the executive is not going to realize the value that you’re reading in the table,” she said. The values for such options that are listed on a company’s proxy statement are based on the value at the time they are issued to the CEO and may go up or down as time passes. “They’ve got 10 years to do it, typically on the term, but the stock price has to exceed, by some measure, what it was at the time of grant,” Stemper added.

Many companies also look at how their competitors compensate their executives as benchmarks for paying their own executives. For example, Illumina’s compensation committee used a peer group of 18 firms to set 2012 compensation levels for their executives, including President and CEO Jay Flatley, whose total compensation for the year dropped 18 percent to $8.2 million.

Among the firms in Illumina’s peer group were

In its proxy, it said that it “considered a number of factors in defining the peer group, including industry competitors of similar revenue range, net income, growth rates, employee size, and market capitalization range that we believe reflects the market for talent and stockholder investment.”

Illumina said that it targets its direct compensation to its executives at between the 60th percentile and 75th percentile of compensation that executives in its peer group receive. The largest component of the total direct compensation is delivered through equity-based awards in order to retain its executives, while aligning their interests with those of its shareholders, it said in its proxy, although it may “deviate from these general target levels to reflect the executive’s experience, the executive’s sustained performance level, and market factors as deemed appropriate by the compensation committee.”

Such a peer group approach, though, also provides challenges, because in such a niche market, the pool of such firms is shallow, Stemper said, and different firms may be at different stages of the business cycle. They may not have similar experiences in terms of success and regulatory approvals, either, or may have dissimilar financial dynamics.

Because of this, firms often include in their benchmark peer groups companies that may be analogous to where they are in terms of their business but which have only the vaguest connection, if any, to what they do. Affymetrix, for instance, included in its peer group for 2012 Nordion, a health science firm that provides targeted therapies, sterilization technologies, and medical isotopes. Genomic Health, meanwhile, looked at, among others, ultrasound shop FujiFilm Sonosite to determine its compensation levels, and Thermo Fisher Scientific had diversified manufacturing and technology company Emerson Electric in its peer group.

In niche markets, such as the omics tools/MDx space, “it will be difficult to simply say ‘I want to look at the median'” compensation offered by competitors, Stemper said. “It’s more likely going to be ‘I want to look at the universe at a dataset level and understand where we believe our CEO fits in best.'”

2012 Winners

Among the firms in the GWDN Index, the CEO with the highest year-over-year compensation increase in 2012 was Thermo Fisher’s Marc Casper, whose total compensation climbed 146 percent to almost $13.6 million from $5.5 million in 2011. The uptick was largely driven by a stock award of $10.4 million granted in 2012, compared to none in 2011.

Two other CEOs whose compensation doubled year over year in 2012 were Bruker’s Frank Laukien, who took in $1.9 million last year, compared to $892,100 in 2011, and Exact Sciences’ Kevin Conroy, whose compensation reached $2.7 million from $1.3 million in 2011.

Frank Witney of Affymetrix had the biggest year-over-year drop, 76 percent, as his 2012 compensation of $657,291 was down from $2.7 million in 2011. The drop-off is largely attributable to a decrease in stock awards in 2012 to $115,750, compared to $1.4 million the year before. Witney became president and CEO of Affy on July 1, 2011.

Another whose compensation narrowed significantly was Waters’ Douglas Berthiaume, who made $1.1 million in 2012, down 60 percent from $2.6 million the year before. Also, William Moffitt, the former CEO of Nanosphere, who was succeeded this past February by Michael McGarrity, saw his compensation fall 48 percent to $457,885 in 2012 from $885,946 in 2011.

And GenMark Diagnostics’ Hany Massarany’s 2012 compensation was down 33 percent at $1.3 million last year from $2.0 million in 2011.

Among the CEOs of firms in the GWDN Index, Danaher’s Lawrence Culp raked in the most in compensation last year, making $21.9 million in total compensation, up from $21.7 million in 2011. Four others made more than $10 million in 2012: Thermo Fisher’s Casper; William Sullivan of Agilent with $10.1 million; Life Technologies’ Greg Lucier with $10.3 million; and PerkinElmer’s Robert Friel with $10.8 million.



Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN


Track 5

Next-Gen Sequencing Informatics

NGS, Genome-Scale Screening, and HTP Proteomics

Track 5 is dedicated to advances in analysis and intepretation of next-gen data. Topics to be covered include analysis of

sequence variants related to cancer research from NGS data, instruments facilitate a cloud approach for NGS, analysis tools

and workflows, and network biology/network medicine.


7:00 am Workshop Registration and Morning Coffee

8:00 Pre-Conference Workshops*

*Separate Registration Required

2:00 – 7:00 pm Main Conference Registration

4:00 Event Chairperson’s Opening Remarks

Cindy Crowninshield, RD, LDN, Conference Director, Cambridge

Healthtech Institute

4:05 Keynote Introduction

Kevin Brode, Senior Director, Health & Life Sciences, Americas Hitachi

Data Systems


Do Network Pharmacologists Need Robot Chemists?

Andrew L. Hopkins, DPhil, FRSC, FSB, Division of Biological Chemistry

and Drug Design, College of Life Sciences, University of Dundee

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

Drop off a business card at the CHI Sales booth for a chance to win 1 of 2

iPads® or 1 of 2 Kindle Fires®!*

*Apple ® and Amazon are not sponsors or participants in this program


7:00 am Registration and Morning Coffee

8:00 Chairperson’s Opening Remarks

Phillips Kuhl, Co-Founder and President, Cambridge Healthtech Institute

8:05 Keynote Introduction

Sanjay Joshi, CTO, Life Sciences, EMC Isilon


Atul Butte, M.D., Ph.D., Division Chief and Associate Professor,

Stanford University School of Medicine; Director, Center for Pediatric

Bioinformatics, Lucile Packard Children’s Hospital; Co-founder,

Personalis and Numedii

8:55 Benjamin Franklin Award & Laureate Presentation

9:15 Best Practices Award Program

9:45 Coffee Break in the Exhibit Hall with Poster Viewing

Best Practices for Genomic Data Interpretation & Analysis

10:50 Chairperson’s Remarks

Steve Dickman, Founder & CEO, CBT Advisors, Inc.

11:00 CLARITY Challenge

Shamil Sunyaev, Ph.D., Associate Professor, Division of Genetics,

Department of Medicine, Brigham and Women’s Hospital/Harvard

Medical School

11:30 HLA and KIR Typing from NGS Reads with

Omixon Target

Attila Berces, Ph.D., CEO, Omixon

HLA is the most polymorphic region of the human genome

with several segmental duplications and its analysis is a computational

challenge. In this presentation I will show examples including validation

studies of HLA typing from various sources of genomic data: whole genome,

whole exome, targeted amplicon sequencing with Illumina, Ion Torrent and

Roche sequencer.

11:45 Comparison of Genome Analysis Tools

Jason Wang, Co-founder & CTO, Arpeggi, Inc.

A major impediment to clinical sequencing is the paucity of

analysis standards and comparison metrics. We present our

progress towards developing analysis standards, as well an open-access

collaborative tool that enables anyone to define comparison metrics and

compare tool performance. We hope that in making available this resource

we can help fuel a community-driven solution for standardizing genome

analysis pipelines.

12:00 Case Study: Sequencing Informatics System to Profile Genetic

Changes in Tumors

Long Phi Le, M.D., Ph.D., Department of Pathology, Massachusetts

General Hospital

This presentation will discuss the development of a sequencing informatics

system to profile genetic changes in tumors that is in collaboration between

PerkinElmer with Massachusetts General Hospital. This system, based on

PerkinElmer’s Geospiza platforms, will allow genotype analysis to define

key targets.

12:30 Ion Torrent Informatics Enables

Semiconductor Sequencing

Darryl León , Ph.D., Associate Director, Product

Management, Ion Torrent, Life Technologies

Data generated by the Ion Torrent Personal Genome Machine Sequencer or

the Ion Torrent Proton Sequencer are analyzed by Torrent Suite Software.

An overview of the data analysis steps will be provided. Torrent Suite offers

a flexible plug-in system allowing software developers the ability to deliver

custom analysis solutions using the compute resources associated with the

local Torrent Server. For researchers with need for either rich annotations

or controlled data analysis, the Ion Reporter Software offers a streamlined

data analysis and decision engine for use with amplicons, exomes,

or genomes.

1:40 Chairperson’s Remarks

Jeffrey Rosenfeld, Ph.D., IST/High Performance & Research Computing,

University of Medicine & Dentistry of New Jersey (UMDNJ)

Sponsored by

Sponsored by

Sponsored by

Bio-ITWorldExpo.com 18

1:45 Data Intensive Academic Grid (DIAG): A Free Computational Cloud

Infrastructure Designed for Bioinformatics Analysis

Anup Mahurkar, Executive Director, Software Engineering and IT, Institute

for Genome Sciences, University of Maryland School of Medicine

We have deployed the NSF funded Data Intensive Academic Grid (DIAG),

a free computational cloud designed to meet the analytical needs of

the bioinformatics community. DIAG has 200+ registered users from 130

institutions worldwide who conduct large-scale genomics, transcriptomics,

and metagenomics data analysis. Learn about the grid’s architecture, how

to access this free resource, and success stories.

2:15 Performance Comparison of Variant Detection Tools for Next

Generation Sequencing (NGS) Data: An Assessment Using a Pedigree-

Based NGS Dataset and SNP Array

Ming Yi, Ph.D. IT Manager, Functional Genomic Group, Advanced

Biomedical Computing Center, SAIC-Frederick at Frederick National

Laboratory for Cancer Research (formerly National Cancer Institute)

There is an urgent need for the NGS community to be able to make the

right choice out of a large collection of available SNP detection tools. Our

methodology offers a great example of comparing SNP discovery tools and

paving a way to expand such methods in more global scope for comparison.

2:45 Informatics in the Cloud

Karan Bhatia, Ph.D., Solutions Architect, Amazon

Web Services

Learn about how to easily create sophisticated, scalable,

secure pipelines to accelerate life science research with Amazon Web

Services. In this presentation, you will learn how to drive scale out, tightly

coupled and Hadoop based workflows on Amazon EC2, a utility computing

platform that provides a perfect fit for data management and collaboration.

3:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Gene Mapping & Expression

3:45 InSilico DB Genomic Datasets Hub: An Efficient Starting Point for

Managing and Analyzing Genomewide Studies in GenePattern, Integrative

Genomics Viewer, and R/Bioconductor

David Weiss, Ph.D., CEO, InSilico Genomics

Alain Coletta, Ph.D., Co-Founder and CTO, InSilico Genomics

The InSilico DB platform is a powerful collaborative environment, with

advanced capabilities for biocuration, datasets subsetting and combination,

and datasets sharing. InSIlico DB solution architecture will be presented

along with a live demo of the InSilico DB online platform. Learn how more

than 1000 users from top academic and research institutions are using

InSilico DB in their daily research.

4:15 Constructing a Comprehensive Map for Molecules Implicated in

Obesity and Its Induced Disorders

Kamal Rawal, Ph.D., Faculty, Biotechnology and Bioinformatics, Jaypee

Institute of Information Technology

We have constructed a comprehensive map of all the molecules (genes,

proteins, and metabolites) reported to be implicated in obesity. This map

paves the way to understanding the pathophysiology of obesity and identify

drug targets and off-targets for existing drugs. This talk discusses the

integrated approach we used in combining public resources, abstracts, and

research articles to construct this map.

4:45 Quality Assurance: An Essential Step for Gene

Expression Analysis Using Deep Sequencing

Dan Kearns, Director, Software Development, Maverix

Biomics, Inc.

Dave Mandelkern, CEO & Co-Founder, Maverix Biomics, Inc.

With the advancement of deep sequencing technologies, researchers

expect to obtain high quality results from their studies. However, this cannot

be obtained solely by successful sequencing runs. Multiple data checks

and pre-processing must be performed before downstream analysis. In this

case study, we will present an automated quality assurance pipeline that

helps improve gene expression analysis results.

5:00 DDN LS Appliance – Simple Platform for NGS

Analysis, Data Distribution and Collaboration

Jose L. Alvarez, WW Director Life Sciences,

DataDirect Networks

With this unique approach the DDN LS appliance can deliver flexible data

ingest options, optimized data analysis resources, a policy based data

tiering/archive solution and a geo-distributed secure collaboration platform.

The appliance delivers 1.46X better performance on popular LS applications

like Bowtie when compared to NFS based solutions.

5:15 Best of Show Awards Reception in the Exhibit Hall

6:15 Exhibit Hall Closes


7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or

Morning Coffee

Gene Mapping & Expression

8:45 Chairperson’s Opening Remarks

8:50 Network Biology and Personalized Medicine in Multiple Sclerosis

Mark Chance, Ph.D., Vice Dean for Research, Proteomics, Case Western

Reserve University

Almost nothing is known about biological factors underlying the remarkable

disease heterogeneity observed across multiple sclerosis (MS) patients,

and there are no accurate biological predictors of disease severity that

can be used for guiding clinical treatment options. Learn about the network

biology methods we are using to analyze blood cell gene expression and

understand good and poor responders to therapy.

9:20 GeneSeer: A Flexible, Easy-to-Use Tool to Aid Drug Discovery by

Exploring Evolutionary Relationships between Genes across Genomes

Philip Cheung, Bioinformatics Group Leader, Scientific Computing,

Dart Neuroscience

GeneSeer is a publicly available tool that leverages public sequence data,

gene metadata information, and other publicly available data to calculate

and display orthologous and paralogous gene relationships for all genes

from several species, including yeasts, insects, worms, vertebrates,

mammals, and primates such as human. This talk describes GeneSeer’s

underlying methods and the user-friendly interface.

9:50 Sponsored Presentations (Opportunities Available)

10:20 Coffee Break in the Exhibit Hall and Poster Competition

Winners Announced

10:45 Plenary Keynote Panel Chairperson’s Remarks

Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World

10:50 Plenary Keynote Panel Introduction

Yury Rozenman, Head of BT for Life Sciences, BT Global Services

Niven R. Narain, President & CTO, Berg Pharma

»»Plenary Keynote Panel

11:05 The Life Sciences CIO Panel


Remy Evard, CIO, Novartis Institutes for BioMedical Research

Martin Leach, Ph.D., Vice President, R&D IT, Biogen Idec

Andrea T. Norris, Director, Center for Information Technology (CIT)

and Chief Information Officer, NIH

Gunaretnam (Guna) Rajagopal, Ph.D., VP & CIO – R&D IT, Research,

Bioinformatics & External Innovation, Janssen Pharmaceuticals

Cris Ross, Chief Information Officer, Mayo Clinic

Matthew Trunnell, CIO, Broad Institute of MIT and Harvard

Sponsored by

Sponsored by

Sponsored by

19 Bio-ITWorldExpo.com

12:15 Luncheon in the Exhibit Hall with Poster Viewing

Panel Session: Building the IT Archetecture of the New York

Genome Center

2:00 Panel Session: Building the IT Architecture of the New York

Genome Center

Moderator: Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World

Christopher Dwan, Acting Senior Vice President, IT, New York

Genome Center

Kevin Shianna, Senior Vice President, Sequencing Operations, New York

Genome Center

Sanjay Joshi, CTO, Life Sciences, EMC Isilon Storage Division

Robert B. Darnell, M.D., Ph.D., President & Scientific Director, New York

Genome Center

George Gosselin, CTO, Computer Design & Integration LLC

In 2011, a consortium of 11 major academic and medical organizations in

and around New York announced the creation of the New York Genome

Center (NYGC). Under the direction of Nancy Kelley, the NYGC aspires to

be a world-class genomics and medical research center, and is currently

undergoing construction in the heart of Manhattan. NYGC management

has the opportunity to design and create a state-of-the-art IT and data

management infrastructure to handle, store and share the output from

what will rapidly become one of the world’s foremost genome sequencing

facilities. This series of talks will describe the thinking that went into the

design, creation and construction of the NYGC’s IT infrastructure and entire

data management strategy.

4:00 Conference Adjourns


Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN


Highlights from 8th Annual Personalized Medicine Conference, November 28-29,  2012, Harvard Medical School, Boston, MA — Method used “Tweets Content Analysis”



  • Audience poll: 75% think a hypothetical cancer diagnostic is patentable, but the number plummets to 25% if that Dx is DNA-based.


  • 30% of #PMConf audience says lack of physician education & awareness is biggest obstacle to adoption of #personalizedmedicine in the clinic


  • 30% of #PMConf audience says lack of physician education & awareness is biggest obstacle to adoption of #personalizedmedicine in the clinic


  • Cost of informatics can be a bottleneck, but technology pushes boundaries & advances


  • “next generation sequencing will become the sole platform for molecular diagnostics”



  • 56% of #PMConf audience thinks that DNA sequence will become a routine part of an individual’s medical record within the next 10 years


  • Programs @AmerMedicalAssn are being developed to support physicians as genetic medicine is put into practice



  • “We have the ability and the technology. It just needs to be applied appropriately”



  • Information is only going to grow & change over time. We’ll always be interpreting our genomes


  • audience comment on need to adjust insurance system to use genetic info, encourage prevention and disease management


  • We need to be cognizant of how economics can affect the delivery of healthcare





  • Audience poll: 75% think clinical whole-genome sequencing useful in select situations only (vs say standard for all…




  • After 10 years of the genomic revolution, #genomics is entering clinical medicine at an accelerated rate


SELECTIVE Live TWEETS from the conference are recorded below:


David Resnick (@NixonPeabodyLLP): Patents have the potential to prevent folks from getting into next generation sequencing #PMConf#NGS

David Resnick @NixonPeabodyLLP & Laura Coruzzi @JonesDaydiscuss Myriad gene patent case @ #PMConf

Audience poll: 75% think a hypothetical cancer diagnostic is patentable, but the number plummets to 25% if that Dx is DNA-based. #PMConf

RT @nixonpeabodyllp: We’ll be live tweeting the next hour of the@HarvardPMConf. NP’s David Resnick talking #genetics & law.#PMConf

Dr. Bob Tepper (Third Rock) introduces panelists from @JonesDay@NixonPeabodyLLP @kpcb for a discussion on genetics & the law#PMConf

Dr. Joshi (@Oracle) – Clinicians must communicate w/ researchers to faithfully implement standards & avoid redundant infrastructures#PMConf

30% of #PMConf audience says lack of physician education & awareness is biggest obstacle to adoption of #personalizedmedicinein the clinic

Joshi (@Oracle) – Cost of informatics can be a bottleneck, but technology pushes boundaries & advances #personalizedmedicine#PMConf

Trevor Hawkins (@SiemensHealth) says “next generation sequencing will become the sole platform for molecular diagnostics” #PMConf

Kevin Hrusovsky @PerkinElmer Personalized medicine evolving into personalized health with addition of prevention & detection #PMConf

 Retweeted by PM Conference

56% of #PMConf audience thinks that DNA sequence will become a routine part of an individual’s medical record within the next 10 years

Kris Joshi @Oracle_at_HIMSS comments on the likely transformation of healthcare into a truly global network #PMConf

Beginning now: panel discussion on “Business Models for Use of Genetic Information,” moderated by Dr. Brophy of @GEHealthcare#PMConf

Dr. Scott says “In next 10-20 yrs, anyone in any developed healthcare system will have access to #genomesequencing#PMConf

RT @bioitworld: Randy Scott: It’s Metcalfe’s Law on network effect — not Moore’s Law — that drove computing boom, and will by…

Dr. Randall Scott (@Genomic_Health & InVitae Corporation): “Every disease is a rare disease & #genomics will help us prove this”#PMConf

Ed Abrahams & Stafford O’Kelly (PMC) present Award for Leadership in #PersonalizedMedicine to Randall Scott (InVitae Corporation) at#PMConf

Panel highlights need for drug developers to collaborate with Dx companies & build partnerships throughout development process.#PMConf

 Retweeted by PM Conference

Pharma engaging in solid partnerships w/ FDA to try new approaches to #drugdevelopment, says Dr. Yancopoulos #PMConf

Dr. Hakan Sakul @pfizer_news begins Q&A session, asking about changing attitudes of the use of #genetics in #drugdevelopment#PMConf

Dr. Yancopoulos @ Regeneron Pharma comments that the ability to humanize mouse models has had great impact on#drugdevelopment #PMConf

Michael Streit @GSKUS: “One size does not fit all. Thinking beyond one pathway mutation is necessary to help #cancer patients”#PMConf

Jeff Leiden @VertexPharma on Genetics & #DrugDevelopment panel @ #PMConf “Need to think about diff molecules to treat specific disease”

Biggest barrier to widespread use of genetics in drug dvlpmt: 29% say attitude of drug dvlprs, 22% say regulatory considerations#PMConf

Retweeted by PM Conference

Audience poll at #PMConf: 84% say #genetics is making a meaningful impact on #drugdevelopment

Heidi Rehm @PartnersNews @harvardmed expresses need for more communication btw physicians & scientists in world of genomic analysis #PMConf

Jon Retzlaff explains @AACR work to advance#personalizedmedicine, including Cancer Biomarkers Collaborative w/ @theNCI @US_FDA #PMConf

Retweeted by PM Conference

Programs @AmerMedicalAssn are being developed to support physicians as genetic medicine is put into practice #PMConf – Katie Johansen Taber

Randy Burkholder @PhRMA – “#personalizedmedicine is the solution to the healthcare cost challenge that we all face” #PMConf

Joe Beery (@LIFECorporation): “We have the ability and the technology. It just needs to be applied appropriately” #PMConf

Dr. Snyder @SUMedicine: Information is only going to grow & change over time. We’ll always be interpreting our genomes#PMConf

Beery agrees w/ audience comment on need to adjust insurance system to use genetic info, encourage prevention and disease management #PMConf

 Retweeted by PM Conference

Dr. Holmes Morton (The Clinic for Special Children): We need to be cognizant of how economics can affect the delivery of healthcare#PMConf

John Lauerman, reporter @BloombergNews comments on his diagnosis with the JAK-2 gene variation and benefits of#genomesequencing #PMConf

Joe Beery @LIFECorporation shares the “medical odyssey” of his children and his personal experience with #rarediseases at #PMConf

Dr. Michael Snyder @SUMedicine discusses #genomics integration into medicine, may lead to a shift to predictive healthcare #PMConf

RT @bioitworld: Audience poll: 75% think clinical whole-genome sequencing useful in select situations only (vs say standard for all…

Dr. Stephen Eck of @AstellasUS begins a panel discussion on the impact of #genomesequencing #PMConf

Dr. Kucherlapati @harvardmed polls #PMConf audience: 75% of attendees think #personalizedmedicine is being built into medical practice

Dr. Jeffrey Filer @harvardmed discusses key impacts of#personalizedmedicine across multiple disease areas #PMConf

Dr. Weiss @PartnersNews: After 10 years of the genomic revolution,#genomics is entering clinical medicine at an accelerated rate#PMConf


Conference Introduction

The past few years have witnessed a revolution in the understanding of health and disease, brought on in large part by the sequencing of the human genome and the creation of a map of human genetic variation. Personalized medicine is the translation of this knowledge to patient care by using genetic and genomic information in diagnosis, prognosis and treatment. The goal of personalized medicine is to provide the right diagnosis and treatment to the right patient at the right time at the right cost. Already there are abundant examples that personalized medicine is poised to transform healthcare by offering the possibility of improved health outcomes and the potential to make healthcare more cost-effective.

The eighth annual Personalized Medicine conference will take place November 28-29, 2012 at The Joseph B. Martin Conference Center at Harvard Medical School in Boston. This year’s two-day conference will once again bring the most current updates on Personalized Medicine and how recent experience may guide and inform the policies, plans and actions of stakeholders among government, academe and the private sector. Widely considered the premier event in the field, the conference attracts over 600 national and international thought leaders.

The conference reflects a distinctive collaboration of the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Harvard Business School. The alliance of these renowned academic enterprises presents an exceptional opportunity to address the integrating of medicine and business in facilitating personalized medicine.

Wednesday, November 28, 2012
7:00 a.m. Registration and Continental Breakfast
8:00 a.m.
Welcome & Opening Remarks
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
Scott Weiss, M.D., M.S.
Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine; Associate Director, Channing Laboratory; Professor of Medicine, Harvard Medical School
Jeffrey Flier, M.D.
Dean of the Faculty of Medicine, Harvard Medical School
Introducer:  Jeffrey Leerink
Chair and CEO, Leerink Swann LLC
8:30 a.m.
Impact of Genome Sequencing
on Health
Human genome sequencing promises to be an important tool in assessing risk, diagnosing disease and stratifying patient populations for targeted therapy.  The panelists will describe some personal experiences of receiving sequence information and talk about how this rapidly growing technology is transforming medical practice.
Moderator: Stephen Eck, M.D., Ph.D.
Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development, Inc.
Joe Beery
Senior Vice President & Chief Information Officer, Life Technologies
John Lauerman
Reporter-at-Large, Bloomberg News
D. Holmes Morton, M.D.
Clinic Director, The Clinic for Special Children
Michael Snyder, Ph.D.
Stanford University School of Medicine
9:45 a.m. Perspectives From Professional Organizations
Randy Burkholder
Deputy Vice President, Policy
Pharmaceutical Research and Manufacturers of America (PhRMA)
Heidi Rehm, Ph.D., FACMG
Director, Laboratory for Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine; Assistant Professor of Pathology, Harvard Medical School
Jon Retzlaff
Managing Director, Office of Science Policy & Government Affairs, American Association for Cancer Research (AARC)
Katherine Johansen Taber, Ph.D.
Senior Scientist, American Medical Association
10:15 a.m.
Networking Break
11:00 a.m.

Genetic Basis for Drug Development

Many drug developers are beginning to successfully use genetic information and genetic markers in drug development.  This panel will provide perspectives from three different companies on how they have used and are using genetic information in successful drug development.
Moderator:  Hakan Sakul, Ph.D.
Executive Director, Head of Diagnostics, Worldwide R&D, Clinical Research and Precision Medicine, Pfizer, Inc.
Jeffrey Leiden, M.D., Ph.D.
President & CEO, Vertex Pharmaceuticals
Michael Streit, M.D., M.B.A.
Executive Director, GlaxoSmithKline-Oncology
George D. Yancopoulos, M.D., Ph.D.
President, Research Laboratories and  Chief Scientific Officer , Regeneron Pharmaceuticals, Inc.
12:00 noon
Presentation of Personalized Medicine Coalition’s Eighth Annual Award for Leadership in Personalized Medicine


Award Recipient: Randall Scott, Ph.D.
Founder and Director, Genomic Health, CEO, InVitae Corporation
Introduction:  Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition
Presenter: D. Stafford O’Kelly
Chairman of the Board, Personalized Medicine Coalition
12:30 p.m.
1:45 p.m.
Business Models for Use of Genetic Information
The discussion should highlight new business opportunities for large companies, such as the three represented on the panel and for small businesses in the services and IT sectors.
Moderator:  Ger Brophy, Ph.D.General Manager, New Product Development, Medical Diagnostics, GE Healthcare
Kris Joshi, Ph.D.
Global Vice President, Healthcare Strategy, Oracle
Trevor Hawkins, Ph.D.
Chief Strategy Officer, Siemens Healthcare Diagnostics
Kevin Hrusovsky
President of Life Sciences & Technology, PerkinElmer
2:45 p.m.

Genetics and the Law

There are conflicting views regarding Intellectual Property for genetic tests.  The panel will offer opposing views on prominent recent litigation and consider how investors see the impact of the legal decisions.
Moderator: Robert Tepper, M.D.
Partner, Third Rock Ventures
Laura Coruzzi, Ph.D., J.D.
Partner, Jones Day
David Resnick, Esq.
Partner, Co-Leader Patents, Nixon Peabody
Risa Stack, Ph.D.
Partner, Kleiner Perkins Caufield & Byers
3:45 p.m.
Networking Break
4:15 p.m.
International  Commitments to Personalized Medicine
Many countries are considering and developing plans to implement the principles of personalized medicine.  Are there lessons from these efforts that the U.S. can learn from?  How can we make personalized medicine a world-wide effort?
Moderator: Jeffrey Elton, Ph.D.
Managing Director, Accenture
Prof. Abraham Israeli, M.D., M.P.H., M.B.A.
Chief Scientist of the Ministry of Health, Head, Department of Health Policy, Health Care Management and Health Economics, Hebrew University – Hadassah Faculty of Medicine; Professor, Hewbrew University – Hadassah School of Public Health, Jerusalem, Israel
Michael Hayden, M.D., Ph.D.
Director and Senior Scientist, Center for Molecular Medicine and Therapeutics, University of British Columbia, Canada
Prof. Ola Myklebost, Ph.D.
Senior Scientist and Group Leader, Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Norway
Ming Qi, Ph.D.Professor, Zhejiang UniversitySchool of Medicine, China
5:15 p.m.
Reception at Elements Café
Thursday, November 29, 2012
7:30 a.m.
Registration & Continental Breakfast
8:30 a.m.
William Hait, M.D., Ph.D.
Global Head of Janssen R&D, Johnson & Johnson

Introducer: John Niederhuber, M.D.
Professor of Oncology & Surgery, Johns Hopkins University School of Medicine; Former Director of the National Cancer Institute; Executive Vice President, Inova Health System; CEO, Inova Translational Medicine Institute
9:00 a.m.

Genetics in Medical Practice

Each institution represented in this panel is making efforts to bring personalized medicine to their patients What are the different approaches that are being used? How are they evolving? What kinds of investments are necessary to build these enterprises? How do these efforts inform us about the progress of personalized medicine?
Moderator: M. Kathleen Behrens Wilsey, Ph.D.
President & CEO, KEW Group
Joe Vockley, Ph.D.
Chief Operating Officer,
Chief Scientific Officer
Inova Translational Medicine Institute
A. John Iafrate, M.D., Ph.D.
Associate Chief of Pathology, Massachusetts General Hospital, Center for Integrated Diagnostics
Mia Levy, M.D., Ph.D.
Assistant Professor of Biomedical Informatics, Assistant Professor of Medicine, Cancer Clinical Informatics Officer, Vanderbilt Ingram Cancer Center
10:00 a.m. Networking Break
10:30 a.m.
Molecular Diagnostics and Public Policy
Will bringing molecular diagnostics into routine practice require bringing together many interest groups and educating and informing regulatory and legislative bodies about the importance of personalized medicine and the need for policy change? What changes are needed? How and by whom the views can best be presented to policy makers and legislators?
Moderator: Amy Miller, Ph.D.
Vice President, Public Policy, Personalized Medicine Coalition
Alan Mertz
President, American Clinical Laboratory Association
Richard Naples
Sr. Vice President, Regulatory Affairs,
BD Biosciences
Paul Radensky, M.D.
Partner, McDermott Will & Emery
11:30 a.m.
Ethical Aspects of Whole Genome Sequencing
Lisa Lee, Ph.D., M.S.
Executive Director, Presidential Commission for the Study of Bioethical Issues
Robert Green, M.D., M.P.H.
Associate Professor of Medicine, Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School; Associate Director for Research, Partners HealthCare Center for Personalized Genetic Medicine
12:00 noon
 Bag Lunch
 Open Seating
1:00 p.m.
Decision Making in the Development
of Zelboraf
Roche and Plexxicon collaborated in developing a targeted therapy for a subset of melanoma patients.  How did the two companies decide to collaborate?  What were the mechanics of the collaboration?  How did the submission of a NDA with a companion diagnostic come about?  What lessons can be drawn from this experience?
K. Peter Hirth, Ph.D.
CEO, Plexxikon
Suzanne Cheng, Ph.D.
Director, Genomics & Oncology Research, Roche Molecular Systems, Inc.
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
1:45 p.m.
Lt. Col.  Cecili K. Sessions, M.D., M.P.H., FAAP
Chief, AFMS Personalized Medicine, Air Force Medical Support Agency (AFMSA), Medical Research &  Innovations (SG5I)
Introducer: Heidi Rehm, Ph.D., FACMG
Director, Laboratory for Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine; Assistant Professor of Pathology, Harvard Medical School
2:15 p.m. Industry Study on Interpretation
Anthony Flynn
Chief Marketing Officer, Director of Healthcare Strategy and Commercialization, GenomeQuest
2:20 p.m.
Interactive Case Study on Business Strategies for Personalized Medicine
Case: Companion Diagnostics: Uncertainties for Approval and Reimbursement
Richard Hamermesh, D.B.A.
MBA Class of 1961 Professor of Management Practice, Faculty Chair, HBS Healthcare Initiative, Harvard Business School
Norman Selby
Executive Chairman, Physicians Interactive Inc. and Real Endpoints llc
3:35 p.m.
Closing Remarks
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
Joe Beery
Joe Beery is Chief Information Officer for Life Technologies and served the same role at Invitrogen since September 2008. Prior to Invitrogen, Mr. Beery held the executive position of Chief Information Officer at US Airways and America West Airlines. Previously, Mr. Beery spent ten years at Motorola Semiconductor, holding various positions in the computer integrated manufacturing group. Mr. Beery also served as a manufacturing and software engineer at NV Philips in Albuquerque, N.M. Mr. Beery holds a B.S. in business administration and business computer systems from the University of New Mexico.

Ger Brophy, Ph.D.
Ger Brophy, Ph.D. is General Manager, New Product Development at GE Healthcare Medical Diagnostics. In this role, Ger is responsible for the overarching R&D strategy encompassing in vivo and in vitro diagnostic technologies, with oversight of discovery (research) and clinical development; regulatory and medical affairs; project and portfolio management; product acquisition and licensing; R&D efficiency projects and collaborations across GE.
Previously, Ger led Strategic Planning & Licensing within Medical Diagnostics business. He was centrally involved in the expansion of the business into the Personalized Medicine space through inorganic and organic investments in in vitro diagnostics and pathology.
Ger joined GE Healthcare through the acquisition of Amersham in 2004. Before joining the Medical Diagnostics business, Ger ran the Life Sciences Advanced Systems business in Sweden. The focus on that business was in the commercialization of improved tools for drug discovery. In that capacity he lead an R&D group of 200 researchers developing new products and services used in academia and Pharma to better understand disease.
Ger began his career in R&D developing high throughput drug screening tools. He advanced to become Development Director for Amersham’s Bioassay’s business unit, leading a group of 60 people. Within GE Healthcare he has held positions in Licensing, Business Development and R&D.
Ger has had international assignments in the UK, Sweden and in Chicago & New Jersey. He relocated to New Jersey in August 2009.
Ger holds a Ph.D. in Molecular Biology.

Randy Burkholder
Randy Burkholder is Deputy Vice President of Policy at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder directs PhRMA work on issues related to use of evidence in healthcare decision-making, health technology assessment, comparative and cost-effectiveness research, Medicare coverage policy, and innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, the Federal Coordinating Council for Comparative Effectiveness Research, Institute of Medicine Committees, and President’s Council of Advisors on Science and Technology. He also is a founding member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care.
Mr. Burkholder has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.
Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.
Suzanne Cheng, Ph.D.
Suzanne Cheng, Ph.D. is currently a Director in the Genomics and Oncology Research Department at Roche Molecular Systems, overseeing several assay teams that support the early development of companion diagnostic assays in oncology. She was the IVD Lead for vemurafenib, a targeted therapy for treatment of patients with BRAF V600E mutation-positive metastatic or inoperable melanoma that was approved in 2011 together with a companion diagnostic, the cobas® 4800 BRAF V600 Mutation Test. She has experienced first-hand the challenges of drug and diagnostic co-development from early development through to successful FDA approvals.
Prior to joining Genomics and Oncology, Dr. Cheng was a member of the Human Genetics Department, contributing to the development of long PCR technology and the evaluation of genetic predisposition markers for the development and progression of cardiovascular disease. She received her degree from the University of California, Berkeley.

Laura Coruzzi, Ph.D., J.D.
Laura Coruzzi, Ph.D., J.D. has represented clients in biotechnology and pharmaceuticals for close to 30 years. Prior to joining Jones Day, she practiced at Pennie & Edmonds LLP and was one of the first members of that firm’s biotechnology group founded by S. Leslie Misrock, affectionately known as the “father of biotechnology patent law.” Laura’s practice has evolved with the patent laws and matured with the needs of the biotechnology and pharmaceutical industries. Her practice involves all aspects of patent law as it relates to a variety of disciplines in the life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery.
Laura’s patent procurement practice focuses on strategic planning and management of patent portfolios designed to protect emerging new technologies as well as mature biologic and pharmaceutical therapeutics and diagnostics. She counsels clients on portfolio evaluation, due diligence investigations, patent prosecution and interferences, European oppositions, and licensing. Laura’s practice also encompasses patent litigation and appeals before the USPTO Board of Appeals and the Federal Circuit. She is a member of the Jones Day team representing Myriad in Association for Molecular Pathology v. Myriad Genetics (2011) upholding the patent-eligibility of isolated human genes. Prior to joining Jones Day, she and her team won reversal of an $18 million jury verdict in 2000 for Cadus Pharmaceutical Corporation in a case involving cell-based assays for drug screening.
Laura is frequently invited to speak at symposia on patent law issues related to life sciences.

Stephen Eck, M.D., Ph.D.
Stephen Eck, M.D., Ph.D is Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development including both early phase clinical studies and late stage drug development studies.  His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population.  An essential part of this work was conducted in the Diagnostic and Experimental Medicine Group and the Laboratory for Experimental Medicine. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).
Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science. He serves on the Scientific Advisory Board of the ACGT Foundation, which supports academic cancer research, and is a member of the Scientific Advisory Committee of the Fairbanks Institute, an institution dedicated to developing data banks to enable personalized medicine. He also serves on the Advisory Board of the Keck Graduate School (Claremont, CA), and is a Board member of the Personalized Medicine Coalition.

Jeffrey Elton, Ph.D.
Jeff Elton, Ph.D. is Managing Director in Life Sciences in Accenture. Jeff has over 20 years of experience as a global executive and consultant in the biopharmaceutical and healthcare sectors. Jeff serves clients in pharmaceutical, biopharmaceutical, and health provider sectors. Jeff also co-leads Accenture’s pilot initiative in the application of health data analytics to pharmaceutical managed markets, commercial, and clinical development analytics.
Recently, Jeff was founding CEO of a Personalized Oncology Company, and Board member and senior advisor to four early stage companies in protein therapeutics, diabetes, oncology therapeutics, and oncology diagnostics.
From 2004 through 2009, Jeff served as Senior Vice President of Strategy and Global Chief Operating Officer at Novartis Institutes of BioMedical Research, Inc. (NIBR) in Cambridge, MA. He led the definition of therapeutic area strategies, formed strategic partnerships, and oversaw global operations in the US, Europe, and Asia.
Prior to Novartis, Jeff was a senior partner with McKinsey & Company for pharmaceutical & medical products practice where he focused on healthcare delivery strategies, new product launches, global commercial management structures, and R&D performance.
Jeff is currently a board member of the Massachusetts Biotechnology Council, a board and executive committee member of the Elizabeth Glaser Pediatric AIDS Foundation, and faculty member of the Boston University School of Management, Health Management Program.

Jeffrey Flier, M.D.
Jeffrey Flier, M.D. is one of the country’s leading investigators in the areas of obesity and diabetes. His research has produced major insights into the molecular mechanism of insulin action, the molecular mechanisms of insulin resistance in human disease, and the molecular pathophysiology of obesity.
Flier was born in New York City. He received a BS from City College of New York in 1968, and an MD from Mount Sinai School of Medicine in 1972, graduating with the Elster Award for Highest Academic Standing. Following residency training in internal medicine at Mount Sinai Hospital from 1972 to 1974, Flier moved to the National Institutes of Health as a Clinical Associate. In 1978, he joined the Faculty of Medicine at Harvard Medical School, serving as Chief of the Diabetes Unit at Beth Israel Hospital until 1990, when he was named chief of the hospital’s Endocrine Division.
In 2002, Flier was named Chief Academic Officer of BIDMC, a newly created senior position responsible for research and academic programs. He worked with Beth Israel Deaconess academic department chairs to ensure the quality and breadth of academic programs at the Medical Center, through which most Harvard Medical School students pass. He also served as the formal liaison to Harvard Medical School, sitting on the Council of Academic Deans.
Flier has authored over 200 scholarly papers and reviews and has held many editorial positions. An elected member of the Institute of Medicine and a fellow of the American Academy of Arts and Sciences, Flier’s honors also include the Eli Lilly Award of the American Diabetes Association, the Berson Lecture of the American Physiological Society, and Honorary Doctorates from the University of Athens and the University of Edinburgh. He was the recipient of the 2003 Edwin B. Astwood Lecture Award from the Endocrine Society, and In 2005, he received the Banting Medal from the American Diabetes Association, its highest scientific honor.
Flier, the father of two daughters, lives in Newton, MA with his wife Eleftheria Maratos-Flier, MD, who is a Professor of Medicine at Harvard Medical School and with whom he has collaborated on research in the area of neuroendocrine

Robert C. Green, M.D., M.P.H.
Robert C. Green, M.D., M.P.H. is a medical geneticist and a clinical researcher who directs the G2P research program (genomes2people.org) in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Green is principal investigator of the NIH-funded REVEAL Study, in which a cross-disciplinary team has conducted 4 separate multi-center randomized clinical trials collectively enrolling 1100 individuals to disclose a genetic risk factor for Alzheimer’s disease in order to explore emerging themes in translational genomics. Dr. Green also co-directs the NIH-funded PGen Study, the first prospective study of direct-to-consumer genetic testing services and leads the MedSeq Project, the first NIH-funded research study to explore the use of whole genome sequencing in the clinical practice of medicine.
Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine, a Board Member of the Council for Responsible Genetics and a member of the Informed Cohort Oversight Boards for both the Children’s Hospital Boston Gene Partnership Program and the Coriell Personalized Medicine Collaborative. He co-chairs the ACMG working group that is currently developing recommendations for management of incidental findings in clinical sequencing.

William N. Hait, M.D., Ph.D.
William N. Hait, M.D., Ph.D. is Global Head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson. In this role, he leads the global R&D group in its mission to discover and develop innovative new medicines to address the world’s most serious unmet medical needs.
Dr. Hait joined Johnson & Johnson in 2007 as Senior Vice President, Worldwide Head of Hematology and Oncology, Ortho Biotech Oncology R&D, and assumed the role of Global TA Head, Oncology, in 2009.
Prior to joining Johnson & Johnson, he was the founding Director of The Cancer Institute of New Jersey and Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School from January 1993 to March 2007. Under Dr. Hait’s leadership, The Cancer Institute of New Jersey was successful in obtaining cancer center designation from the National Cancer Institute in 1996 and received the National Cancer Institute’s highest designation of Comprehensive Cancer Center in 2002.
After earning his B.A. from the University of Pennsylvania, Dr. Hait received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania, where he was elected to Alpha Omega Alpha. He joined the Yale University School of Medicine faculty in 1984 and was quickly promoted to Associate Professor of Medicine and Pharmacology. Dr. Hait served as Associate Director of the Yale University Comprehensive Cancer Center and Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit at the Yale University School of Medicine. He was appointed Chief of Medical Oncology at the Yale University School of Medicine in 1988. Dr. Hait is Board Certified in Internal Medicine and Medical Oncology.
Dr. Hait is a member of the Medical Advisory Board of both the New Jersey Breast Cancer Coalition and Susan G. Komen Foundation and is an active member on Scientific Advisory Boards of several universities. He served on various committees for the American Association for Cancer Research (Chair, Clinical Cancer Research Committee), American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors), and the National Cancer Institute Board of Scientific Advisors. Dr. Hait served as President of the American Association for Cancer Research from 2007 – 2008, and is currently serving as treasurer.

Richard Hamermesh, D.B.A.
Richard Hamermesh is the MBA Class of 1961 Professor of Management Practice at the Harvard Business School where he teaches in the MBA Program and is the Faculty Chair of the HBS Healthcare Initiative. Richard created and teaches the second-year MBA elective, Entrepreneurship and Venture Capital in Healthcare. Previously, he was the Course Head for the required first year course entitled The Entrepreneurial Manager. In addition Richard participates in several HBS Executive Education programs.
From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.
Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. These have included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. He is currently on the Boards of one public and two private corporations, as well as two non-profit Boards. From 1991 to 1996, he was the founding Chairman of Synthes Spine, Inc. Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published numerous articles and more than 100 case studies. His most recent article, “Realizing the Potential of Personalized Medicine”, appeared in the Harvard Business Review(October 2007). Richard received his AB from the University of California, and his MBA and DBA from HBS. He is married, has two children, and his hobbies include tennis, skiing, and yoga.

Trevor Hawkins, Ph.D.
Trevor Hawkins, Ph.D., as the past Director of the Human Genome Project for the US DOE, has built a recognized career in the healthcare industry over the past 20 years spanning business, academic innovation and as an entrepreneur.
Dr. Hawkins is the Senior Vice President of Strategy and Innovation for Siemens Healthcare Diagnostics.
Prior to joining Siemens he has held several senior executive roles, as Chief Scientific Officer of Royal Philips Electronics focusing on healthcare, CEO of Philips Molecular Healthcare business unit, CEO of GEs Molecular diagnostics business and President of Amershams Genomics business. He was also Chairman & CEO of ProGenTech, a privately held company based in Shanghai & San Francisco.
Dr. Hawkins invented SPRI, Solid Phase Reversible Immobilization the magnetic bead nucleic acid isolation method that was used extensively as the sample prep method for the Human Genome Project. The SPRI patent remains as one of the most important in the field of magnetic bead use for life sciences and diagnostics.
Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project. He was also a founder of the Beijing Genome Institute (BGI), Chinas’ genome program and remains an Honorary Professor of the BGI.
Dr. Hawkins has served on several public and private Boards and is currently involved in non-profit organizations in California.

Michael Hayden, M.D., Ph.D.
Michael Hayden, M.D., Ph.D. is the Killam Professor of Medical Genetics at the UBC and Canada Research Chair in Human Genetics and Molecular Medicine. He is the Director of the Center for Molecular Medicine and Therapeutics (CMMT) and founder of three biotechnology companies: NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp.
Author of over 700 peer-reviewed publications and invited submissions, Michael focuses his research primarily on genetic diseases, including genetics of lipoprotein disorders, Huntington disease, predictive and personalized medicine. Michael and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. Michael also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition. Michael is also the most cited author in the world for ABCA1 and Huntington Disease.
Michael is the recipient of numerous recent prestigious honours and awards, including the Margolese National Brain Disorder Prize (2011), awarded to Canadians who have made outstanding contributions to the treatment, amelioration, or cure of brain diseases; the Killam Prize by the Canada Council of the Arts (2011), in recognition of his outstanding career achievements; and the Canada Gairdner Wightman award (2011), recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. Michael has also been awarded the Order of Canada (2011), and the Order of British Columbia (2010). He was named Canada’s Health Researcher of the Year by CIHR in 2008, and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research.

K. Peter Hirth, Ph.D.
K. Peter Hirth, Ph.D. co-founded Plexxikon in December 2000, and has over 25 years of biotechnology and pharmaceutical discovery and development experience. Plexxikon was built as a novel, structure-guided drug discovery platform. Over the last ten years, Plexxikon has brought several NCEs into the clinic in a variety of indications. Most advanced from this portfolio is a selective B-raf V600 inhibitor that has been approved by the FDA for the treatment of patients with BRAFV600E mutation-positive inoperable or metastatic melanoma, as detected by an FDA-approved test, and is sold under the brand name Zelboraf®. Plexxikon was acquired in April 2011 by Daiichi Sankyo and is now a member of the Daiichi Sankyo Group.
Previously, Peter was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. This includes the drug Sutent, now owned by Pfizer through its acquisition of Pharmacia. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company’s erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.

E. Kevin Hrusovsky
E. Kevin Hrusovsky was appointed President, Life Sciences & Technology, PerkinElmer in November 2011 when Caliper Life Sciences (CALP) was acquired. This transaction was the culmination of significant value creation for the CALP stakeholders. In July 2003, Hrusovsky became CEO of Caliper Life Sciences, when Zymark Corporation was acquired by Caliper. Subsequently, Caliper acquired and integrated three additional innovative tools companies and made substantial R&D and commercialization investments. Through these actions, Hrusovsky and Team transformed Caliper into a leading edge personalized medicine / health technology company. The Company’s rapid growth in sales and market valuation over the past three years made Caliper one of the fastest growing innovative life science technology companies in the industry, and a credible resource for articulating these important trends in medicine and health. Prior to the acquisition, Hrusovsky served as President and CEO for Zymark starting in late 1996, where he successfully transformed Zymark from a custom robotics company into a formidable Life Sciences tools company. From 1992 to 1996, he was Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division, for FMC Corporation. From 1983 to 1992, he held several management positions at E.I. DuPont de Nemours, including North American Sales and Marketing Head, Teflon.
Hrusovsky currently sits on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. He formerly served on the boards of SeraCare Life Sciences, Caliper Life Sciences, Xenogen Corporation and Alliant Medical Technology. Hrusovsky received an Honorary Doctorate degree from Framingham State University for contributions to life sciences. He received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University. He and his family are authentic Buckeyes!

Professor Abraham Israeli, M.D., M.P.H., M.B.A.
Professor Abraham (Avi) Israeli, M.D., M.P.H., M.B.A. is Chief Scientist of the Ministry of Health, and the Head of the Health Policy, Health Care Management and Health Economics Department at the Hebrew University – Hadassah Faculty of Medicine. Prior to this he was the Director General of the Israel Ministry of Health (2003-2009) and the Director – General of Hadassah Medical Organization (1998 -2001).  He holds the Chair of Dr. Julien Rozan Professorship of Family Medicine and Health Promotion Chair at the Hebrew University-Hadassah Medical School, Jerusalem (since 1996) and teaches there regularly.
Professor Israeli chaired the national committee to update the Israeli national standard basket of health services.
Professor Israeli received his medical degree and his master in public health from the Hadassah – Hebrew University Medical School. He completed residencies in Internal Medicine and in Health-Care Management at Hadassah University Hospital and has certification in both specialties. He received his Master’s Degree from the Sloan School of Management at MIT, Boston.
His scientific activities are related to applied, methodological and theoretical research in the fields of health policy, health care management, and the epidemiological, economic, social and cultural basis for decision-making.
His publications deal with translation of academic knowledge and inputs from the field into policy setting and decision-making processes.
Two additional key research foci are rationing / priority setting and comparative health care systems.

Kris Joshi, Ph.D.
Kris Joshi, Ph.D.  is Global Vice President responsible for Oracle’s Healthcare product portfolio. Kris helped launch the Health Sciences Global Business Unit within Oracle, and led the business unit’s growth strategy, including the acquisitions of Relsys and Phase Forward. He oversees a product portfolio that covers Analytics, Health Information Exchange, Care Management, and solutions for Personalized Medicine and Translational Research serving healthcare payer, provider and life sciences segments.
Prior to Oracle, Kris served in senior strategy roles in IBM’s Global Sales & Distribution organization where he helped shape IBM’s global distribution strategy and emerging markets strategy. Prior to IBM, Kris spent several years as a consultant with McKinsey and Co where he served Fortune 500 clients in Banking, Media, Healthcare and Life Sciences industries on business strategy issues. Kris has a long-standing personal commitment to help bridge the gap between the social and business worlds through entrepreneurship, innovation, and public-private partnerships. He has championed numerous initiatives aimed at leveraging technology to improve the quality, safety, and affordability of healthcare globally.
Kris holds a Bachelor of Science in Mathematics from CalTech and a Ph.D. in Astrophysics from MIT.

Raju Kucherlapati, Ph.D.
Raju Kucherlapati, Ph.D. is the Paul C.Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital. Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. During 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.
He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. He is a member of Presidential Commission for the Study of Bioethical Issues.
Dr. Kucherlapati received his B.S. and M.S. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

John Lauerman
John Lauerman is a reporter-at-large at Bloomberg News writing about health and higher education. Lauerman and his colleagues won a Polk Award and were Pulitzer finalists in 2011 for a series of stories on for-profit colleges that recruit low-income students, often to leave them with debt and no degree. The series also won a Gerald Loeb Award, a National Headliner Award, and the Education Writers Association Grand Prize. In 2010, he won a New York Press Club award for coverage of Harvard University’s $1 billion loss on risky investments. He won a 2009 award from the Society of the Silurians for his stories on the failed search for a vaccine against HIV. His team won a 2005 award from the Society of American Business Writers and Editors for coverage of Merck & Co.’s withdrawal of the painkiller Vioxx after it was linked to heart disease. He has been a fellow of the Blue Cross Blue Shield of Massachusetts Health Coverage program and the Kaiser Family Foundation’s program for science journalists. Before coming to Bloomberg, Lauerman was a science writer at Harvard Medical School from 1985 thorugh 1988. Later, as a freelance journalist, he wrote a health column for Harvard Magazine, contributed to newspapers and magazines across the U.S., and edited the public health journal “Health and Human Rights.” He is the co-author of two books: “Diabetes: Understand Your Condition, Make the Right Treatment Choices, and Cope Effectively,” and “Living to 100.” He lives with his wife and two children in Brookline, Massachusetts.

Lisa M. Lee, Ph.D., M.S.
Lisa M. Lee, Ph.D., M.S., is the Executive Director of the Presidential Commission for the Study of Bioethical Issues. Lee previously had been with the Centers for Disease Control and Prevention (CDC) since 1998, most recently serving as Chief Science Officer in the Office of Surveillance, Epidemiology, and Laboratory Sciences.
Lee, who has a Ph.D. from Johns Hopkins and an M.S. in bioethics from Alden March Bioethics Institute at Albany Medical College, is an epidemiologist, surveillance scientist, and public health ethicist. Lee’s work at CDC has included ethics of public health surveillance, scientific integrity, development and evaluation of surveillance systems, research on HIV and fertility, HIV/AIDS survival, HIV and tuberculosis, and data quality. She has led several agency and cross-agency committees working to establish and maintain an environment of scientific integrity and excellence.
Lee is the lead editor of Principles and Practice of Public Health Surveillance, 3d edition (Oxford University Press, 2010). She has authored numerous scientific publications and has served as a peer and guest reviewer for many scientific conferences and scientific journals. She serves on the Board of Advisors and is adjunct faculty at Georgia State University’s Institute of Public Health, where she teaches ethics.

Jeffrey Leiden, M.D., Ph.D.
Jeffrey Leiden, M.D., Ph.D., President, CEO and Chairmanjoined Vertex Pharmaceuticals in December 2011 and served on Vertex’s board since 2009. Dr. Leiden brings to Vertex more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries and clinical experience in academia as a practicing cardiologist and molecular biologist. Dr. Leiden is a Senior Advisor for Clarus Ventures, a life sciences venture capital firm he joined in 2006. In 2000, he joined Abbott Laboratories as President and Chief Operating Officer where he had responsibility for running Abbott’s global pharmaceuticals business. While at Abbott, Dr. Leiden helped launch multiple breakthrough medicines, including Humira for rheumatoid arthritis and other autoimmune diseases and Kaletra for HIV infection, among others. He also served as a member of the Board of Directors of Abbott Laboratories from 2001 to 2006.
Dr. Leiden began his career in academia as a practicing cardiologist and molecular biologist. From 1987 to 2000, Dr. Leiden held several academic appointments, including roles as Chief of Cardiology at the University of Chicago and Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital. During his academic career, Dr. Leiden was also involved in starting several biotechnology companies including Vical and Cardiogene.
Dr. Leiden held a number of board positions for pharmaceutical and biotechnology companies, including the role of non-executive Vice Chairman for Shire Pharmaceuticals plc. He was also a member of the Board of Directors of Millennium Pharmaceuticals, Inc. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Mia Levy, M.D., Ph.D.
Dr. Mia A. Levy is the Director of Cancer Clinical Informatics for the Vanderbilt-Ingram Cancer Center and an Assistant Professor of Biomedical Informatics and Medicine.
Dr. Levy received her undergraduate degree in Bioengineering from The University of Pennsylvania in 1997 and her Medical Doctorate from Rush University in 2003. She then spent 6 years at Stanford University completing post-graduate training in Internal Medicine and Medical Oncology while completing her PhD in Biomedical Informatics. She joined the faculty at Vanderbilt as an Assistant Professor in Biomedical Informatics and Medicine in August 2009. She is a practicing medical oncologist specializing in the treatment of breast cancer.
Dr. Levy’s research interests include biomedical informatics methods to support the continuum of cancer care and cancer research. Current research projects include informatics methods for 1) image based cancer treatment response assessment using quantitative imaging, 2) clinical decision support for treatment prioritization of molecular subtypes of cancer, 3) protocol based plan management and 4) learning cancer systems.

Alan Mertz
Alan Mertz became President of ACLA in 2003 and since that time he has exponentially grown ACLA’s membership, visibility and advocacy efforts.  ACLA has led a series of successful advocacy campaigns on laboratory reimbursement, regulation, coding, health IT and many other issues, including stopping legislation imposing laboratory co-pays in Medicare and repealing a laboratory Medicare competitive bidding project.  ACLA also led industry efforts to ensure that regulatory changes with respect to genetic and molecular testing do not stifle innovation or harm patient care.  ACLA launched the “Results for Life” educational campaign in 2007 to promote the value of laboratory services and in 2009, ACLA started its Associate Member program for non-laboratory health care companies and organizations.
Prior to his current position, Mertz was Executive Vice President and Acting President of the Healthcare Leadership Council (HLC), and prior to that served in three senior staff positions in the House and Senate over 18 years.  He is a frequent lecturer at American University, and was an adjunct professor at George Washington University (both in Washington, DC).  Mertz holds a Masters Degree in American Politics from American University and a BA in Government from Monmouth College (IL).

Amy Miller, Ph.D
Amy Miller, Ph.D. is the Vice President of Public Policy for the Personalized Medicine Coalition (PMC) which represents a broad spectrum of academic, industrial, patient, provider, and payer organizations that seek to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. Dr. Miller works with these communities to reach consensus on policy issues impacting personalized medicine and share those views with policy makers.
Before joining the PMC, Dr. Miller worked in the office of the Director of the National Institute of Mental Health where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families. A former AAAS fellow, she also served as a domestic policy advisor to Senator Jay Rockefeller. She began her career as a researcher at National Institute of Child Health and Human Development.
Dr. Miller received a BA from the University of New Orleans and holds a doctoral degree in Human Development from the University of Connecticut.

D. Holmes Morton, M.D.
D. Holmes Morton M.D. is a pediatrician and was the cofounder with his wife Caroline of the Clinic for Special Children in Strasburg Pennsylvania, which Clinic is a non-profit medical center that provides care for children with complex medical problems arising from inherited predispositions to disease. The Clinic for Special Children is located on an Amish farm near Strasburg in Lancaster County Pennsylvania. Although it is a local pediatric medical center, the Clinic has become recognized internationally for innovative studies in the discovery and treatment of inherited disorders. The Clinic’s publications about the treatment of maple syrup urine disease can be found in Pediatrics, Current Treatment Options in Neurology, Molecular Genetics and Metabolism, Brain, Journal of Pediatrics, Pediatric Transplant, Nature, and Gene Reviews.
Holmes Morton graduated from Trinity College in 1979 with Honors in Biology and Psychology and was elected to Pi Beta Kappa. He studied medicine at Harvard Medical School and completed a 3-year Residency in Pediatrics at Children’s Hospital. In 1986 Dr. Morton moved to Children’s Hospital of Philadelphia to study biochemical genetics under Richard Kelley. In 1988, with the support of Hugo Moser, he moved Dr. Kelley’s new laboratory at Kennedy Krieger Institute at Johns Hopkins to develop methods for diagnosis and treatment of the Amish variant of Glutaric Aciduria Type 1. This work led to the establishment of the Clinic for Special Children in Lancaster County Pennsylvania in 1989.
Dr. Morton is a member of the American Academy of Pediatrics and the Society for Inherited Metabolic Disorders. In 1993, he was given the Albert Schweitzer Prize for Humanitarianism, a prize awarded jointly by the Alexander von Humbolt Foundation of Germany and Johns Hopkins University. In 2006 Dr. Morton was awarded a John D. and Catherine T. MacArthur Fellowship

Professor Ola Myklebost, Ph.D.
Ola Myklebost, Ph.D. is Senior Scientist and Group Leader at the Department of Tumor Biology, Institute for Cancer Research, and Professor at the Department for Molecular Biosciences at the University of Oslo. He is also Assistant Director of CAST, the Centre for research-based Innovation (SFI) on Cancer Stem Cells, and previous head of the Norwegian Genomics Consortium. Currently he is heading the Norwegian Cancer Genomics Consortium, with the aim to introduce and investigate the use of tumor genome profiles for therapeutic decisions.

Dr. Myklebost took his MSc under Per Seglen at what is now Dept. of Cell Biology in 1982, then went to St. Mary’s Hospital in London where he worked with recombinant DNA technology under the leadership of Bob Williamson. Returning to Oslo, he worked at the Institute for Internal Medicine at the National Hospital under Hans Prydz until 1987, when he had a research stay in the group of Keith Stanley at EMBL. Since 1988 he has again been employed at the Institute of Cancer Research, now at the Dept. of Tumor Biology. Dr. Myklebost received his Doctor of philosophia from the Medical Faculty, University of Oslo.

Richard Naples
Richard Naples, Senior Vice President of Regulatory Affairs, is responsible for global market access and regulatory compliance functions, including premarket submissions, reimbursement and public policy. He has been with BD for a total of five years.
Mr. Naples has over 30 years experience in medical devices and diagnostics. He has been a chief corporate regulatory officer, an FDA regulator, and a clinical laboratory manager. He is currently co-chair of the AdvaMed Diagnostics Task Force and has been recognized as one of the top regulatory professionals in the industry. His experience includes over 300 successful regulatory submissions and leadership of numerous industry-wide initiatives to ensure more timely patient access to innovative new technologies.
Most recently prior to joining BD, Rick was Roche Diagnostics VP of Regulatory and Government Affairs after serving as a Consumer Safety Officer at FDA HQ Center for Biologics, Evaluation and Research (CBER). He also served on the boards of the New England Healthcare Institute (NEHI) and the Indiana Medical Device Manufacturers Council (IMDMC). Rick holds a Bachelor of Science degree in Chemistry/Medical Technology from Youngstown State University (Ohio).

Ming Qi, Ph.D.
Ming Qi, Ph.D. received his B.S. from South China Normal University in 1982. He received his M.S. from Fudan University, Shanghai in 1985 and was mentored by Dr. C.C. Tan, the “Father of Genetics at China”. He succeeded in the national competition to be a student of the CUSBEA (China-USA Biochemistry / Molecular Biology) Program and received his Ph.D. from the University of Pittsburgh in 1991. Dr. Qi did his postdoctoral training in Dr. Stan McKnight’s Lab, University of Washington from 1991-1994. Dr. Qi had his clinical postdoctoral fellowship in Molecular Genetics with Dr. Peter Byers at the University of Washington from 1994-1998 and was certified in clinical molecular genetics by American Board of Medical Genetics in 1999. He is a Fellow of American College of Medical Genetics. He has been the faculty of University of Rochester Medical School since 1998 as a Assistant Professor, Associate Professor and Professor. Dr. Qi served as a consultant of Harvard Medical School-Partner Center for Genetics and Genomics and Visiting Geneticist of the Laboratory of Molecular Medicine in 2006. His research has been published in numerous peer reviewed scientific journals, including in Nat Genet, PNAS, Cell, Human Mol Genetics, JAMA, Circulation, Am J Med Genet, Human Mutation, etc. He is the Chief Advisor of the Chinese National Gene Health Committee, and the coordinator of the international Human Variome Project Chinese Consortium. He is an editorial board member of several international journals including Human Mutation, Giga-Science and ANE. He also serves as a reviewer for a number of international journals. Dr. Qi has recently been news-report interviewed by Nature and Science (http://www.nature.com/news/2011/110125/full/469455a.html;

Paul Radensky, M.D.
Paul Radensky, M.D. is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Washington, D.C. and Miami offices. Paul is co-chair of the Firm’s Life Sciences Government Strategies team and a member of the Personalized Medicine team.
Paul is a recognized authority on the full range of legal, regulatory and reimbursement issues pertaining to pharmaceutical, biotechnology, medical device, and clinical laboratory development and marketing. His background as a clinical researcher and medical practitioner informs his practical and scientific understanding of both product manufacturers and clinical laboratories. He advises manufacturers at every stage of product development, including the design and monitoring of clinical trials, positioning and applying for FDA approval, maintaining regulatory compliance, and obtaining coverage, coding and payment for new technologies by Medicare, Medicaid and other third party payors. Paul also advises clinical laboratories on CLIA and state licensure compliance as well as evolving policies on FDA regulation of  laboratory-developed tests.
Paul is ranked in The Best Lawyers in America (2009-2012).
Paul is board certified in internal medicine and is a member of the American College of Physicians and the Alpha Omega Alpha Honor Medical Society. He is a member of the District of Columbia Bar as well as the Florida Bar.

Heidi Rehm, Ph.D., FACMG
Heidi Rehm, Ph.D., FACMG is the Chief Laboratory Director for the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine and Assistant Professor of Pathology at Harvard Medical School. She was recruited in 2001 to build the CLIA lab after completing her graduate degree in Genetics from Harvard University and her postdoctoral and fellowship training at Harvard Medical School. The lab focuses on the rapid translation of new genetic discoveries into clinical tests that can be used to improve patient outcomes, supporting the model of personalized medicine. In addition, the lab focuses on bringing novel technologies and software systems into molecular diagnostics to support the integration of genetics into clinical use. The laboratory has been a leader in translational medicine, launching the first clinical tests for cardiomyopathy and lung cancer treatment among many achievements. In 2012, the lab will launch a CLIA-approved interpretive service for whole genome sequencing. Dr. Rehm is involved in defining standards for the use of next generation sequencing in clinical diagnostics through her committee roles at the American College of Medical Genetics and collaborative efforts with the CDC. Dr. Rehm is also involved in a major effort to develop and curate a universal clinical genomic variant database through collaborative efforts with NCBI and many other groups. Dr. Rehm also conducts research in hearing loss, Usher syndrome, cardiomyopathy, and healthcare IT.

David Resnick, Esq.

David Resnick, Esq. is the co-leader of the Patents practice group at Nixon Peabody. His practice is focused on patent prosecution and overall portfolio management, transactional matters, and associated client counseling. David represents, and manages the portfolios of, some of the leading academic research institutions in the U.S., as well as some of the world’s most recognized life science companies. He has extensive experience in the life sciences and is widely regarded as a thought leader in the area of personalized medicine, particularly with respect to pharmacogenomics, proteomics, and disease biomarkers, and their application in the field of personalized medicine.
Jon Retzlaff
Jon Retzlaff is the Managing Director of Science Policy and Government Affairs. Before joining the AACR in 2010, Mr. Retzlaff worked in government relations for Lewis-Burke Associates, LLC and led the firm’s health and biomedical research practice. Previously, he served as legislative director for the Federation of American Societies for Experimental Biology from 2004-2007.
Additionally, he worked for the National Institutes of Health, first as a program analyst within the Office of the Director’s legislative office; then as a senior legislative advisor to the National Institute of Neurological Disorders and Stroke; and finally as the Executive Officer of the National Library of Medicine. Mr. Retzlaff was assigned to the House (1998) and Senate (2000-2001) appropriations subcommittees on labor, health and human services, education and related agencies on health research funding issues, as well as within the Office of the Secretary for Legislation at the Department of Health and Human Services. He entered the Federal Government as a Presidential Management Intern in 1993 and completed a rotation in the Office of Senator Herb Kohl (D-Wis.) during his training.
Mr. Retzlaff earned a Bachelor of Science degree from the University of Minnesota, a master’s degree in public administration from Indiana University and a master’s degree in business administration from the Massachusetts Institute of Technology.

Hakan Sakul, Ph.D.
Hakan Sakul, Ph.D. is a Senior Director in the Translational Oncology Group where he serves as a program manager for Companion Diagnostics. He received his BS and MS degrees from Ankara University in Turkey. He was a recipient of the “Freedom from Hunger Scholarship” from The Rotary Foundation, and completed his PhD degree in Quantitative Genetics from the University of Minnesota (1990) as a Rotary Foundation Scholar. Subsequently, he conducted postdoctoral studies at the University of California-Davis. After spending four years in the biotech industry working in human genetics, pharmacogenomics and statistical genetics fields, Hakan spent a few years at Parke-Davis Pharmaceuticals as the Director of Human Genetics, Statistical Genetics and Pharmacogenetics programs. He then served as Vice President of Statistical Genomics at Ardais Corporation in Boston briefly before returning to Pfizer in 2001 as Director and Site Head for Clinical Pharmacogenomics in Groton/New London Laboratories, with responsibilities across all therapeutic areas. Hakan was promoted to Senior Director in mid-2005 and took on the role of Global Head of Companion Diagnostics for about four years to oversee the companion diagnostics needs across Pfizer’s pharmaceutical portfolio. In 2010, Hakan assumed his current role in the Oncology Business Unit where most of Pfizer’s companion diagnostics needs reside. A member of the Editorial Board of the Personalized Medicine Journal, the Organizing Committee of the annual Personalized Medicine meeting at Harvard, and the author of over 30 scientific refereed articles and several book chapters, Hakan has served as an invited speaker on many scientific meetings and panel discussions. His external representation of Pfizer includes memberships on the Clinical Science and Technology Committee of The Personalized Medicine Coalition, the Research Tools and Molecular Diagnostics Sub Team of BIO, and the California Healthcare Institute’s Diagnostics Working Group. Hakan currently serves as the Co-Chair of Pfizer’s Personalized Medicine team, and is keenly interested in applications of companion diagnostics, pharmacogenomics and related technologies to the pharmaceutical pipeline to advance Personalized Medicine for the improvement of individualized healthcare.


Randall Scott, Ph.D.
Randall Scott, Ph.D. founded Genomic Health in 2000 and led the company as CEO for 9 years with a focus on improving the quality of treatment decisions for patients with cancer. Genomic Health was one of the first companies to translate genomic information into clinical practice by developing the Oncotype DX series of tests for breast, colon, and prostate cancer, each ofwhich is designed to improve the quality of care and reduce healthcare costs. Under his leadership, Genomic Health led a transformation in medical and business practice to incorporate complex genomic tests into routine medical practice with full reimbursement support by national payers. Dr. Scott has played a role in founding several successful biotech companies in addition to Genomic Health Inc. such as Incyte, a leading biopharmaceutical company as well as his newest enterprise InVitae Corporation where he is focused on expanding beyond cancer to bring the power of the human genome into routine medical practice for every individual at risk for common or rare genetic conditions. He is the author of over 40 scientific publications, 20 patents, and is the recipient of numerous awards.

Norman C. Selby
Norman C. Selby has spent 30 years in the healthcare world in a variety of consulting, managerial, investment and Board roles. He is currently Executive Chairman of two innovative healthcare information businesses: Real Endpoints llc and Physicians Interactive Inc. In addition, Mr. Selby serves as a Senior Advisor to Perseus llc, a private equity firm based in Washington, D.C.

Mr. Selby is currently on the Board of three healthcare product companies: Infinity Pharmaceuticals, a leading public (INFI) oncology biotech company, Metamark Genetics, an oncology diagnostics company, and Merz Group GmbH, a global specialty pharma company based in Frankfurt, Germany. In the decade of the 2000s he was on the Board of three other companies all of which had successful exits: Millennium Pharmaceuticals (MLNM) which was acquired by Takeda; TransForm Pharmaceuticals (where he was also CEO) which was acquired by Johnson & Johnson; and Windhover Information (where he was Executice Chairman) which was acquired by Reed Elsevier.
Mr. Selby spent the bulk of his career at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office. He held several leadership roles at McKinsey, including head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. After McKinsey he went to Citicorp/Citigroup where he was an Executive Vice President.
Mr. Selby serves on the Board of Trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center and the Ralph Lauren Center for Cancer Care and Prevention, all based in New York City. He is also a member of the advisory board of the Harvard Business School’s Healthcare Initiative, and a Board member of the National Parks Conservation Association in Washington D.C.
Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.

Lt. Col. Cecili Sessions, M.D., M.P.H., FAAP
Lt Col Cecili K. Sessions, MD, MPH, FAAP is assigned to the United States Air Force Medical Support Agency, Medical Research & Innovations Division, as Chief, Personalized Medicine, and directs the Patient-Centered Precision Care Genomic Medicine Research Program (PC2-Z). Prior to this assignment, she served as the Air Force Liaison to the Armed Forces Health Surveillance Center, the central strategic epidemiological resource for the Armed Forces of the United States. As an active duty pediatrician, she was stationed at Incirlik AB, Turkey, and Kadena AB, Okinawa.
Dr. Sessions received her degree from the Keck School of Medicine at the University of Southern California in 2000, after which she completed a Pediatric Residency at Georgetown University, where she was selected Resident of the Year in her graduating class of 2003.Both her undergraduate degree at Stanford University (AB, 1996) and graduate coursework (MPH, 2007) during the General Preventive Medicine Residency at the Uniformed Services University of the Health Sciences focused on International Health. During her graduate medical education, Dr Sessions completed two externships with the Pan American Health Organization at their headquarters in Washington, D.C.
Michael Snyder, Ph.D.
Michael Snyder, Ph.D. is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has launched many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs between and within species. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Tehcnologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.

Risa Stack, Ph.D.
Risa Stack, Ph.D. is a partner at Kleiner Perkins Caufield & Byers. Since joining the firm in 2003, she has worked to build and support KPCB’s personalized medicine portfolio. Risa has been the founding CEO and a board member of several personalized medicine companies, including CardioDx and Nodality. Risa is a board observer at Tethys, Veracyte and Xdx. In addition to her work directly with portfolio companies, Risa is involved in developing public policy in molecular diagnostics and personalized medicine. Risa is also involved in the development of therapeutics companies, including Corthera and Trius. She was most recently a board member of Corthera (sold to Novartis in 2009), and she is a board observer at Epizyme and Pacific Biosciences.
Risa has 15 years of experience investing in personalized medicine, therapeutics and platform technologies. Her investment career spans from incubations to public companies. Most recently, she has focused on starting companies, often taking operational roles. Before joining KPCB, Risa was a principal at J.P. Morgan Partners in the life science practice for six years. While at J.P. Morgan Partners, she sponsored a series of investments including Acurian, Connetics (acquired by Steifel Laboratories), Diatide (acquired by Berlex), Ilex Oncology (acquired by Genzyme), Illumina, and Triangle Pharmaceuticals (acquired by Gilead). Risa was also involved in JP Morgan Partners’ international investing efforts, which included European life sciences companies and managing a portfolio of Israeli early stage life sciences and IT companies. Before joining the venture capital industry, Risa worked as a derivative specialist on the Chicago Board of Trade, where she traded futures and options on government securities.
Risa received her B.S. degree in genetics and development with distinction from the University of Illinois and her Ph.D. in immunology from the University of Chicago. She was also a member of the second class of Kauffman Fellows. Risa also serves as a member of the advisory board of the National Summit on Personalized Healthcare and GE’s Healthymagination effort. In 2004, Risa was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times.


Michael Streit, M.D., M.B.A.
Michael R. Streit, M.D., M.B.A., is Executive Director at GlaxoSmithKline-Oncology and the Program Physician Leader for the small-molecule GSK1120212 (MEK-inhibitor) clinical development program.
Dr. Streit received his MD from the Free University of Berlin (Germany) in 1985 and did postgraduate training at the Benjamin Franklin Medical Center in Berlin and the Massachusetts General Hospital in Boston.  Prior to joining GSK in 2011, Dr. Streit worked in the field of clinical drug research and development for Bristol-Myers Squibb, Boehringer-Ingelheim Pharmaceuticals, and Berlex Biosciences.
Katherine Johansen Taber, Ph.D.
Katherine Johansen Taber, PhD has been a Senior Scientist at the American Medical Association since 2006. She leads the AMA’s Program in Genetics and Molecular Medicine, which focuses on educating physicians about the clinical implementation of genetics and on identifying emerging genetic policy issues affecting health care providers. She also advises the AMA Board of Trustees and the House of Delegates on genetics issues such as the oversight of genetic testing, gene patenting, stem cell research, and newborn screening. Dr. Johansen Taber has held a position on the Board of NCHPEG since 2006, and will be Vice Chair beginning in 2012. She also serves as the AMA appointment to the Institute of Medicine’s Roundtable on Genomics, and has served as an Advisory Board member for Genetic Services Policy Project and as an advisor for the Illinois Humanities Council’s community genetics education program Future Perfect. Dr. Johansen Taber earned her PhD in Molecular, Cell, and Developmental Biology at the University of California, Los Angeles, and conducted post-doctoral research at the USDA. She has held teaching appointments at UCLA, California State Polytechnic University, University of Idaho, and Columbia College Chicago.

Robert I. Tepper, M.D.
Robert I. Tepper, M.D. is a distinguished scientist with over 25 years of experience building and operating leading R&D operations. Bob co-founded Third Rock Ventures in 2007 and focuses on the formation, development and scientific strategy of our portfolio companies as well as actively identifying and evaluating new investments. He also assumes active leadership roles in our portfolio companies, functioning as Chief Scientific Officer through the first 12-18 months post launch.
Prior to joining Third Rock Ventures, Bob was President of R&D at Millennium Pharmaceuticals and was vital in its expansion from a drug discovery company to a fully-integrated biopharmaceutical company. Prior to Millennium, Bob co-founded Cell Genesys/Abgenix.
Bob holds an AB in Biochemistry from Princeton University and received his MD degree from Harvard Medical School. Bob serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, the Massachusetts General Hospital and Tufts Medical School.

Joe Vockley, Ph.D.
Joe Vockley, Ph.D., is Chief Operating Officer and Chief Scientific Officer of the Inova Translational Medicine Institute. Dr. Vockley brings 25 years of experience in academic, pharmaceutical, biotechnology CROs and government research. He has broad and deep expertise in the fields of genetics, genomics, molecular diagnostics, bioinformatics and large program management.
Dr. Vockley is a results-oriented manager and scientist. He is an inventor on numerous US and international genomic and bioinformatic technology patents in the areas of DNA diagnostics, laboratory methods for microarray analysis, gene discoveries and bioinformatic tool development. His basic research interests are in the fields of cancer and inborn errors of metabolism.
Dr. Vockley has previously held the positions of Chief Scientific Officer, Vice President of Research, Director of Genomics and Director of Bioinformatics. Most recently, he was the director of National Cancer Institute’s Cancer Genome Atlas Project and The Cancer Genome Atlas Program Office.

Scott Weiss, M.D., M.S.
Scott Weiss, M.D., M.S. is currently Scientific Director of the Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) and Associate Director, Channing Laboratory, and Professor of Medicine at Harvard Medical School. In this latter capacity, he leads a 28 investigator, 120 person research group examining the environmental and genetic origins of asthma and COPD.
He has authored or coauthored over 500 publications and four books in the area of asthma and COPD risk factors, natural history, and genetics. His initial work concerned the role of airways responsiveness and environmental tobacco smoke exposure in asthma and COPD, the effect of allergen exposure and airways responsiveness on markers of inflammation and the combined effect of these factors on the development of COPD. In 1996, he developed a strong interest in the genetics of asthma and his work over the past 14 years has focused on this, and novel environmental exposures such as vitamin D and the bowel flora. His laboratory is the only laboratory in the world that has active NIH research in the areas of asthma genetics, asthma pharmacogenetics, and COPD genetics. He is the principal investigator or co-investigator on a total of six separate NHLBI-funded grant proposals in the area of the genetics of asthma and Asthma Pharmacogenetics, including a MERIT award.

M. Kathleen Behrens Wilsey, Ph.D.
M. Kathleen Behrens Wilsey, Ph.D. served as a Member of the President’s Council of Advisors on Science and Technology (PCAST), from 2001 to 2009, working on multiple national policy matters. She Chaired PCAST’s Subcommittee on Personalized Medicine and led a two year study that culminated in the September 15, 2008 report, Priorities for Personalized Medicine. Kathy was a director of the Board on Science, Technology and Economic Policy (STEP) for the National Research Council from 1997-2005, at which time she participated as a member of the Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer. Kathy was a director of the National Venture Capital Association from 1993 to 2000, also serving as President, Chairman and Past Chairman from October of1999 through April of 2000. Dr. Behrens Wilsey currently serves as a member of the Board of Directors of Sarepta Therapeutics, Inc. and KEW Group Inc. Kathy holds a Ph.D. in Microbiology from the University of California, Davis.
Kathy established a career in the financial services industry, working with Robertson Stephens & Co. until 1996, where she became a general partner and managing director. Dr. Behrens Wilsey continued in her capacity as a General Partner for selected venture funds for RS Investments, after management led a buy-out of that firm from Bank of America. Her professional career includes tenures as a public-market life-sciences securities analyst, as well as venture capitalist focusing on healthcare and technology investments. She was instrumental in the founding of several life-sciences companies including Protein Design Labs, Inc. and COR Therapeutics, Inc. and participated in financing a broad range of health care services and products companies.
Dr. Behrens Wilsey served as a director of Abgenix, Inc. in a role that spanned that firm’s early rounds of private financings through the company’s sale in 2006 to Amgen, Inc. and was a director of Amylin Pharmaceuticals, Inc. from 2009 until the company’s recent sale in 2012 to Bristol-Myers Squibb Co. Dr. Behrens Wilsey has worked for the last several years with KEW Group Inc. in developing a personalized medicine oncology management company and currently serves as KEW Group’s President & CEO.


Pascale Witz
Pascale Witz is the President and Chief Executive Officer of GE Healthcare’s Medical Diagnostics business (MDx), and an officer of the General Electric Company.
MDx is a $2bn global leader in pharmaceutical and molecular diagnostics which are used by physicians in the early detection, diagnosis, and management of disease.
Since joining MDx in 2009, Pascale has successfully expanded GE Healthcare’s diagnostics capabilities to include molecular diagnostics, broadening the portfolio through acquisition, investment and partnership. Pascale is deeply committed to enabling personalized medicine. She believes that combining in vivo and in vitro diagnostics will drive an integrated solution encompassing risk stratification, early detection, prediction and monitoring, which will enable physicians to diagnose and treat disease more effectively. According to Pascale, precision diagnostics allow us to interrogate the pathways that drive cancer and age-related neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease.
Pascale has more than 16 years of leadership at GE Healthcare including heading the Functional Imaging (Nuclear Medicine and PET) and the CT (Computed Tomography) businesses in EMEA. Prior to her current position, she led GEHC’s global Interventional business, developing innovative medical technologies for interventional radiology and cardiology. Prior to joining GE, Pascale spent five years in the pharmaceutical industry, having started her career working in a molecular biology research laboratory.
She is an active leader in the GE Women’s Network and now serves on its executive board. The GE Women’s Network boasts a membership of over 180,000 women globally with a goal of focusing on the professional development of women throughout the company.
Pascale holds a Master’s degree in life sciences/molecular biology from INSA Lyon, and an MBA from INSEAD.

George Yancopoulos, M.D., Ph.D.
George Yancopoulos, M.D., Ph.D. graduated as valedictorian of both the Bronx High School of Science and Columbia College, and earned his advanced degrees at Columbia University’s College of Physicians and Surgeons. Following widely-recognized work in the field of molecular immunology at Columbia with Dr. Fred Alt, Dr. Yancopoulos left academia in 1989 as founding scientist for Regeneron Pharmaceuticals, where he continues to serve as President of the Laboratories and Chief Scientific Officer. He is also adjunct full professor at Columbia University and was awarded Columbia’s Stevens Triennial prize for Research and the University Medal of Excellence for Distinguished Achievement. Dr. Yancopoulos is widely regarded as a world leader in several fields of biology and has authored more than 350 scientific manuscripts. According to a study by the Institute for Scientific Information, Dr. Yancopoulos was the eleventh most highly cited scientist in the world during the 1990’s. In 2004, he was elected to both the National Academy of Sciences and the American Academy of Sciences. Dr. Yancopoulos’ scientific efforts have focused on the discovery of growth factors (such as the neurotrophins, ephrins and angiopoietins), their receptors, and their signaling pathways, as well as on developing new platforms for target and drug discovery such as Trap TechnologyVelociGene and VelocImmune. His research has led to unifying models of molecular and biologic function, as well as new approaches to treating disease. Dr. Yancopoulos and his team have progressed numerous drug candidates to human trials, including the IL1-Trap (ARCALYST®) which has recently been approved for treatment of an orphan inflammatory disease, the VEGF Trap-Eye (EYLEA®) which has recently been approved for age-related macular degeneration (the most common cause of blindness in the elderly), the VEGF Trap-Onc (ZALTRAP®) for cancer, and several fully human monoclonal antibodies derived using VelocImmune technology for various indications including cholesterol-lowering and inflammatory diseases.

Register online at www.personalizedmedicineconference.org .
Follow the conversation online at @HarvardPMConf and #PMConf.




Read Full Post »

%d bloggers like this: